Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial

Nyang'wa, Bern-Thomas, Kloprogge, Frank, Moore, David AJ, Bustinduy, Amaya, Motta, Ilaria, Berry, Catherine and Davies, Geraint R ORCID: 0000-0002-3819-490X (2021) Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial. BMJ OPEN, 11 (9). e047185-.

Text
Population pharmacokinetics and pharmacodynamics of investigational regimens drugs in the TB-PRACTECAL clinical trial (the P.pdf - Published version
Download (797kB) | Preview

Official URL: http://dx.doi.org/10.1136/bmjopen-2020-047185

Abstract

<h4>Introduction</h4>Drug-resistant tuberculosis (TB) remains a global health threat, with little over 50% of patients successfully treated. Novel regimens like the ones being studied in the TB-PRACTECAL trial are urgently needed. Understanding anti-TB drug exposures could explain the success or failure of these trial regimens. We aim to study the relationship between the patients' exposure to anti-TB drugs in TB-PRACTECAL investigational regimens and their treatment outcomes.<h4>Methods and analysis</h4>Adults with multidrug-resistant TB randomised to investigational regimens in TB-PRACTECAL will be recruited to a nested pharmacokinetic-pharmacodynamic (PKPD) study. Venous blood samples will be collected at 0, 2 and 23 hours postdose on day 1 and 0, 6.5 and 23 hours postdose during week 8 to quantify drug concentrations in plasma. Trough samples will be collected during week 12, 16, 20 and 24 visits. Opportunistic samples will be collected during weeks 32 and 72. Drug concentrations will be quantified using liquid chromatography-tandem mass spectrometry. Sputum samples will be collected at baseline, monthly to week 24 and then every 2 months to week 108 for MICs and bacillary load quantification. Full blood count, urea and electrolytes, liver function tests, lipase, ECGs and ophthalmology examinations will be conducted at least monthly during treatment.PK and PKPD models will be developed for each drug with nonlinear mixed effects methods. Optimal dosing will be investigated using Monte-Carlo simulations.<h4>Ethics and dissemination</h4>The study has been approved by the Médecins sans Frontières (MSF) Ethics Review Board, the LSHTM Ethics Committee, the Belarus RSPCPT ethics committee and PharmaEthics and the University of Witwatersrand Human Research ethics committee in South Africa. Written informed consent will be obtained from all participants. The study results will be shared with public health authorities, presented at scientific conferences and published in a peer-reviewed journal.<h4>Trial registration number</h4>NCT04081077; Pre-results.

Item Type:	Article
Uncontrolled Keywords:	Humans, Tuberculosis, Multidrug-Resistant, Drugs, Investigational, Antitubercular Agents, Microbial Sensitivity Tests, Prospective Studies, Adult, Randomized Controlled Trials as Topic
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences
Depositing User:	Symplectic Admin
Date Deposited:	31 Jan 2022 16:41
Last Modified:	18 Jan 2023 21:14
DOI:	10.1136/bmjopen-2020-047185
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3147902